세계의 충혈 제거제 시장 : 제품 유형, 처방 구분, 카테고리, 용도, 연령층, 유통 채널, 지역별(-2035년)

Global Decongestant Market Research Report by Product Type (Synthetic Decongestants, Aromatic Decongestants, Herbal Decongestants, Combination), by Formulation (Nasal, Oral, Topical), by Category (Prescription Based, Over the Counter), by Application (Nasal Allergies, Cold, Asthma, Rhinits, Sinusitis, Nasal Polyps, Others), by Age Group (Peditrics, Adults, Geriatrics), by Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies), and by Region (North America, Europe, Asia Pacific, South America, Middle East and Africa) Forecast till 2035

Industry Overview

The global decongestant market will witness steady growth, increasing from USD 28,965.35 million in 2024 to USD 57,810.82 million in 2035, at a 6.48% CAGR throughout 2025-2035. Decongestants are drugs that provide temporary relief from blocked or stuffy noses by shrinking swollen tissues inside the nasal passages. They target blood vessels to reduce swelling and allow easier breathing. Widely sold as over-the-counter remedies, they are used for common colds, allergic rhinitis, and sinus-related issues.

Respiratory diseases are still among the major health concerns all over the earth, which is the reason why the need for decongestants still holds the highest place in the healthcare market. The rising frequency of colds, flu, hay fever, and sinus infections, which is a trend that has been going on for a while and worsened by urban air pollution, has been driving the consumption of nasal sprays, oral tablets, and inhalers. Respiratory pollutants such as PM and NO2 are tailored to trigger the already chronic respiratory disorders in patients who thus rely heavily on decongestant therapies. The demand is not only persistent but also augmented by seasonal outbreaks. The market for healthcare continues to expand as a necessary segment of self-care healthcare solutions, as respiratory cases surge in both developed and underdeveloped worlds.

Key Company Development

Sanofi takes significant steps in the decongestant industry with innovation and strategic expansion. They are stimulating their R&D efforts to attract the launch of the very first photo-sensitive formulations, including variants of multi-symptom combination therapies and natural decongestants. The trend with consumers towards safety and holistic treatment is exactly the direction that the Sanofi company is taking. Sanofi is also leveraging strategic collaborations with healthcare providers and emerging startups to strengthen its position in the growing herbal and alternative remedies segment. To further diversify its portfolio, the company is considering acquisitions of firms with established expertise in natural ingredient-based products.

Key Players

Major players in the global decongestant market are Pfizer, Johnson & Johnson, Sanofi, Cipla Ltd, AptarGroup, Inc., Perrigo Company PLC, PANADOL, and Procter & Gamble Company.

Report Attribute Details

Market Size 2024 USD 28,965.35 Million

Market Size 2035 USD 57,810.82 Million

CAGR (2025-2035) 6.48%

Base Year 2024

Market Forecast Period 2025-2035

Historical Data 2019-2024

Market Segmentations

By Product Type: Synthetic Decongestants - 6.35%, Aromatic Decongestants - 6.56%.

By Formulation: Nasal - 6.61%, Oral - 6.74%.

By Category: Prescription-Based - 6.04%, Over the Counter - 6.64%

By Application: Nasal Allergies - 6.75%, Cold - 6.72%.

By Age Group: Pediatrics - 6.96%, Adults - 6.64%

By Distribution Channel: Hospital Pharmacies - 6.02%, Drug Stores & Retail Pharmacies - 6.62%.

Regional Analysis

The North American market benefits from the widespread availability of decongestants through retail pharmacies and e-commerce platforms. High prevalence of sinusitis and asthma drives consistent product demand. North America's strong position, reaching USD 10,975.78 million in 2024, reflects advanced distribution networks and high consumer reliance on decongestants for seasonal allergies.

Europe's cold weather, which makes respiratory disorders more common, contributes to the continent's need for decongestants. Nasal sprays, drops, and oral decongestants are consistently available because of robust pharmaceutical supply chains. With USD 8,641.87 million, Europe shows consistent demand bolstered by more self-care behaviors and supportive laws for over-the-counter medications.

The market is expanding rapidly in the Asia-Pacific region due to urban air pollution, which is a major cause of respiratory issues. OTC drugs are becoming more and more popular among Southeast Asian and Indian middle-class communities. With a valuation of USD 6,967.03 million, the Asia Pacific market is growing quickly as the usage of over-the-counter and prescription decongestants is increased by urbanization and rising income levels.

South America is showing steady growth, supported by increasing healthcare spending and greater awareness of respiratory treatments. Brazil's large population makes it the dominant market, while Argentina and Chile show growing preference for OTC drugs. Rising internet penetration is also boosting online sales of decongestants.

Rising healthcare expenditure and a growing focus on accessible medicines are driving the MEA market. Gulf Cooperation Council (GCC) countries are emerging as strong contributors with the rapid adoption of modern pharmacy networks. Africa is gradually overcoming barriers of affordability and accessibility, making decongestants more widely available.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 RESEARCH OBJECTIVE
• 2.3 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 DATA MINING PROCESS
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 SECONDARY RESEARCH DATA FLOW:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 PRIMARY RESEARCH DATA FLOW:
  • 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
  • 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 CONSUMPTION & NET TRADE APPROACH
  • 3.6.2 REVENUE ANALYSIS APPROACH
• 3.7 DATA FORECASTING
  • 3.7.1 DATA FORECASTING TECHNIQUE
• 3.8 DATA MODELING
  • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
  • 3.8.2 DATA MODELING:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
  • 4.1.1 INNOVATION IN DRUG FORMULATIONS AND DELIVERY SYSTEMS
  • 4.1.2 HEALTHCARE ACCESSIBILITY AND REGULATION
  • 4.1.3 RISING DEMAND FOR NASAL SPRAYS AND INHALERS
• 4.2 DRIVERS
  • 4.2.1 INCREASING INCIDENCE OF RESPIRATORY DISEASES
  • 4.2.2 GROWING POPULARITY OF SELF-MEDICATION
• 4.3 RESTRAINTS
  • 4.3.1 STRINGENT REGULATORY GUIDELINES
  • 4.3.2 SIDE EFFECTS AND SAFETY CONCERNS ASSOCIATED WITH DECONGESTANTS
• 4.4 OPPORTUNITY
  • 4.4.1 INCREASED DEMAND FOR NATURAL AND HERBAL DECONGESTANTS
  • 4.4.2 DEVELOPMENT OF COMBINATION THERAPIES TARGETING MULTIPLE SYMPTOMS
• 4.5 IMPACT ANALYSIS OF COVID-19
  • 4.5.1 IMPACT ON OVERALL HEALTHCARE
  • 4.5.2 IMPACT ON GLOBAL DECONGESTANT MARKET
  • 4.5.3 IMPACT ON SUPPLY CHAIN OF GLOBAL DECONGESTANT MARKET
  • 4.5.4 IMPACT ON MARKET DEMAND OF GLOBAL DECONGESTANT MARKET
  • 4.5.5 IMPACT ON PRICING OF GLOBAL DECONGESTANT MARKET

5 MARKET FACTOR ANALYSIS

• 5.1 SUPPLY/VALUE CHAIN ANALYSIS
  • 5.1.1 RAW MATERIAL PROCUREMENT
  • 5.1.2 MANUFACTURING
  • 5.1.3 PACKAGING & LABELLING
  • 5.1.4 DISTRIBUTION AND RETAIL
  • 5.1.5 RETAIL & CONSUMER DEMAND
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 THREAT OF NEW ENTRANTS
  • 5.2.2 THREAT OF SUBSTITUTES
  • 5.2.3 BARGAINING POWER OF SUPPLIERS
  • 5.2.4 BARGAINING POWER OF BUYERS
  • 5.2.5 INTENSITY OF RIVALRY

6 GLOBAL DECONGESTANT MARKET, BY PRODUCT TYPE

• 6.1 INTRODUCTION
  • 6.1.1 SYNTHETIC DECONGESTANTS
  • 6.1.2 AROMATIC DECONGESTANTS
  • 6.1.3 HERBAL DECONGESTANTS
  • 6.1.4 COMBINATION

7 GLOBAL DECONGESTANT MARKET, BY FORMULATION

• 7.1 INTRODUCTION
  • 7.1.1 NASAL
    • 7.1.1.1 NASAL SPRAY
    • 7.1.1.2 NASAL DROPS
    • 7.1.1.3 INHALERS
  • 7.1.2 ORAL
    • 7.1.2.1 TABLETS & CAPSULES
    • 7.1.2.2 LIQUIDS & SYRUPS
  • 7.1.3 TOPICAL
    • 7.1.3.1 GELS
    • 7.1.3.2 PATCHES

8 GLOBAL DECONGESTANT MARKET, BY CATEGORY

• 8.1 INTRODUCTION
  • 8.1.1 PRESCRIPTION-BASED
  • 8.1.2 OVER THE COUNTER

9 GLOBAL DECONGESTANT MARKET, BY APPLICATION

• 9.1 INTRODUCTION
  • 9.1.1 NASAL ALLERGIES
  • 9.1.2 COLD
  • 9.1.3 ASTHMA
  • 9.1.4 RHINITIS
  • 9.1.5 SINUSITIS
  • 9.1.6 NASAL POLYPS
  • 9.1.7 OTHERS

10 GLOBAL DECONGESTANT MARKET, BY AGE GROUP

• 10.1 INTRODUCTION
  • 10.1.1 PEDIATRICS
  • 10.1.2 GERIATRICS

11 GLOBAL DECONGESTANT MARKET, BY DISTRIBUTION CHANNEL

• 11.1 INTRODUCTION
  • 11.1.1 HOSPITAL PHARMACIES
  • 11.1.2 DRUG STORES & RETAIL PHARMACIES
  • 11.1.3 ONLINE PHARMACIES

12 GLOBAL DECONGESTANT MARKET, BY REGION

• 12.1 INTRODUCTION
  • 12.1.1 NORTH AMERICA
    • 12.1.1.1 US
    • 12.1.1.2 CANADA
    • 12.1.1.3 MEXICO
  • 12.1.2 EUROPE
    • 12.1.2.1 GERMANY
    • 12.1.2.2 UK
    • 12.1.2.3 FRANCE
    • 12.1.2.4 ITALY
    • 12.1.2.5 SPAIN
    • 12.1.2.6 TURKEY
    • 12.1.2.7 REST OF EUROPE
  • 12.1.3 ASIA-PACIFIC
    • 12.1.3.1 JAPAN
    • 12.1.3.2 CHINA
    • 12.1.3.3 INDIA
    • 12.1.3.4 SOUTH KOREA
    • 12.1.3.5 INDONESIA
    • 12.1.3.6 MALAYSIA
    • 12.1.3.7 AUSTRALIA
    • 12.1.3.8 SINGAPORE
    • 12.1.3.9 REST OF ASIA PACIFIC
  • 12.1.4 SOUTH AMERICA
    • 12.1.4.1 BRAZIL
    • 12.1.4.2 ARGENTINA
    • 12.1.4.3 REST OF SOUTH AMERICA
  • 12.1.5 MIDDLE EAST & AFRICA
    • 12.1.5.1 SOUTH AFRICA
    • 12.1.5.2 GCC COUNTRIES
    • 12.1.5.3 SAUDI ARABIA
    • 12.1.5.4 REST OF MIDDLE EAST AND AFRICA

13 COMPETITIVE LANDSCAPE

• 13.1 INTRODUCTION
• 13.2 MARKET SHARE ANALYSIS, 2024

14 COMPANY PROFILES

• 14.1 PFIZER.
  • 14.1.1 COMPANY OVERVIEW
  • 14.1.2 PRODUCTS OFFERED
  • 14.1.3 SWOT ANALYSIS
  • 14.1.4 KEY STRATEGY
• 14.2 CIPLA LTD.
  • 14.2.1 COMPANY OVERVIEW
  • 14.2.2 PRODUCTS OFFERED
  • 14.2.3 SWOT ANALYSIS
  • 14.2.4 KEY STRATEGY
• 14.3 GLAXOSMITHKLINE (GSK)/ PANADOL
  • 14.3.1 COMPANY OVERVIEW
  • 14.3.2 PRODUCTS OFFERED
  • 14.3.3 SWOT ANALYSIS
  • 14.3.4 KEY STRATEGY
• 14.4 JOHNSON & JOHNSON
  • 14.4.1 COMPANY OVERVIEW
  • 14.4.2 PRODUCTS OFFERED
  • 14.4.3 SWOT ANALYSIS
  • 14.4.4 KEY STRATEGY
• 14.5 APTARGROUP, INC.
  • 14.5.1 COMPANY OVERVIEW
  • 14.5.2 PRODUCTS OFFERED
  • 14.5.3 SWOT ANALYSIS
  • 14.5.4 KEY STRATEGY
• 14.6 PROCTOR & GAMBLE COMPANY
  • 14.6.1 COMPANY OVERVIEW
  • 14.6.2 PRODUCTS OFFERED
  • 14.6.3 SWOT ANALYSIS
  • 14.6.4 KEY STRATEGY
• 14.7 RECKITT BENCKISER GROUP PLC
  • 14.7.1 COMPANY OVERVIEW
  • 14.7.2 PRODUCTS OFFERED
  • 14.7.3 SWOT ANALYSIS
  • 14.7.4 KEY STRATEGY
• 14.8 SANOFI
  • 14.8.1 COMPANY OVERVIEW
  • 14.8.2 PRODUCTS OFFERED
  • 14.8.3 SWOT ANALYSIS
  • 14.8.4 KEY STRATEGY
• 14.9 PERRIGO COMPANY PLC
  • 14.9.1 COMPANY OVERVIEW
  • 14.9.2 PRODUCTS OFFERED
  • 14.9.3 SWOT ANALYSIS
  • 14.9.4 KEY STRATEGY
• 14.10 DR. REDDY'S LABORATORIES
  • 14.10.1 COMPANY OVERVIEW
  • 14.10.2 PRODUCTS OFFERED
  • 14.10.3 SWOT ANALYSIS
  • 14.10.4 KEY STRATEGY

15 DATA CITATIONS